Evidence map›Paper›PMID 39437797›Full record

GuidelineBlood advances2025

American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary.

Deborah M Siegal, Eric K Tseng, Holger J Schünemann, Pantep Angchaisuksiri, Adam Cuker, Kathryn Dane, Maria T DeSancho, David Diuguid, Daniel O Griffin, Frederikus A Klok and 38 more

Abstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Early Prophylactic-Dose Thromboprophylaxis and 30-Day Mortality in Solid Tumor Patients Hospitalized for COVID-19: A Multicenter Retrospective Cohort Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

48 authors.

Deborah M SiegalDepartment of Medicine and Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.ORCID 0000-0003-3806-3245
Eric K TsengDivision of Hematology/Oncology, St Michael's Hospital, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-2745-8057
Holger J SchünemannDepartment of Health Research Methods, Evidence, and Impact, Department of Medicine, Michael G. DeGroote Cochrane Canada Centre, and McMaster GRADE Centre, McMaster University, Hamilton, ON, Canada.ORCID 0000-0003-3211-8479
Pantep AngchaisuksiriDivision of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Adam CukerDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-3595-5697
Kathryn DaneDepartment of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD.
Maria T DeSanchoDivision of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY.
David DiuguidDivision of Hematology, College of Physicians and Surgeons, Columbia University, New York, NY.
Daniel O GriffinDivision of Infectious Diseases, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY.ORCID 0000-0001-5853-6906
Frederikus A KlokDepartment of Medicine, Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0001-9961-0754
Alfred Ian LeeSection of Hematology, Yale School of Medicine, New Haven, CT.ORCID 0000-0002-5968-3948
Ignacio NeumannEscuela de Medicina, Facultad de Medicina y Ciencia, Universidad San Sebastian, Santiago, Chile.
Ashok PaiDivision of Hematology and Oncology, Kaiser Permanente, Oakland, CA.
Marc RighiniDivision of Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Kristen M SanfilippoDivision of Hematology, Washington University School of Medicine St. Louis, St. Louis, MO.ORCID 0000-0002-0433-7845
Deirdra R TerrellDepartment of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK.ORCID 0000-0003-0794-5851
Elie A AklDepartment of Internal Medicine, American University of Beirut, Beirut, Lebanon.ORCID 0000-0002-3444-8618
Reyad Al JabiriFaculty of Medicine, University of Jordan, Amman, Jordan.
Yazan Al JabiriDivision of Hospital Medicine, Washington University in St. Louis, St. Louis, MO.
Angela M BarbaraCanadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada.
Antonio BognanniDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada Centre, and McMaster GRADE Centre, McMaster University, Hamilton, ON, Canada.ORCID 0000-0003-0128-903X
Imad Bou AklFaculty of Medicine, American University of Beirut School of Medicine, Beirut, Lebanon.
Mary BoulosPostgraduate Medical Education, University of Toronto, Toronto, ON, Canada.ORCID 0000-0001-5046-598X
Romina Brignardello-PetersenDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-6010-9900
Matthew ChanMcMaster GRADE Centre, McMaster University Medical Centre, Hamilton, ON, Canada.
Rana CharideDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-5512-0091
Luis E Colunga-LozanoDepartment of Clinical Medicine, Health Science Center, Universidad de Guadalajara, Guadalajara, Mexico.ORCID 0000-0001-7737-4914
Karin DearnessLibrary Services, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada.ORCID 0000-0002-6854-0156
Andrea J DarziDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada Centre, and McMaster GRADE Centre, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-2498-1697
Heba HusseinDepartment of Oral Medicine, Oral Diagnosis, and Periodontology, Faculty of Dentistry, Cairo University, Cairo, Egypt.ORCID 0000-0001-6042-361X
Samer G KaramDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada Centre, and McMaster GRADE Centre, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-5167-4246
Philipp KolbDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada Centre, and McMaster GRADE Centre, McMaster University, Hamilton, ON, Canada.
Razan MansourUniversity of Kansas Medical Center, University of Kansas, Kansas City, KS.
Gian Paolo MorganoDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada Centre, and McMaster GRADE Centre, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-7577-7963
Rami Z MorsiDepartment of Neurology, University of Chicago, Chicago, IL.ORCID 0000-0003-2131-3711
Giovanna Muti-SchünemannDepartment of Emergency Medicine, University of Milan, Milan, Italy.
Menatalla K NadimDepartment of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.ORCID 0000-0003-1506-3613
Atefeh NooriDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-0141-3718
Binu A PhilipDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada Centre, and McMaster GRADE Centre, McMaster University, Hamilton, ON, Canada.
Thomas PiggottDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.ORCID 0000-0003-1643-5386
Yuan QiuDepartment of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, ON, Canada.ORCID 0000-0002-9572-9106
Yetiani Roldan BenitezDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Finn SchünemannAsklepios Klinik Wandsbek, Hamburg, Germany.
Adrienne StevensDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada Centre, and McMaster GRADE Centre, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-6257-4806
Karla SoloDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada Centre, and McMaster GRADE Centre, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-6134-9140
Wojtek WierciochDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada Centre, and McMaster GRADE Centre, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-6576-1650
Reem A MustafaDivision of Nephrology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.ORCID 0000-0002-2091-0875
Robby NieuwlaatDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada Centre, and McMaster GRADE Centre, McMaster University, Hamilton, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19-related critical and acute illness is associated with an increased risk of venous thromboembolism (VTE). These evidence-based recommendations of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about using anticoagulation for thromboprophylaxis for patients with COVID-19-related critical illness; patients with COVID-19-related acute illness; and those being discharged from the hospital, who do not have suspected or confirmed VTE.

methodsASH formed a multidisciplinary panel, including patient representatives. The Michael G. DeGroote Cochrane Canada and MacGRADE Centres at McMaster University supported guideline development, including performing systematic reviews (up to June 2023). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to assess certainty in the evidence and make recommendations.

resultsThis is an executive summary of 3 updated recommendations that have been published, which concludes the living phase of the guidelines. For patients with COVID-19-related critical illness, the panel issued conditional recommendations suggesting (a) prophylactic-intensity over therapeutic-intensity anticoagulation and (b) prophylactic-intensity over intermediate-intensity anticoagulation. For patients with COVID-19-related acute illness, conditional recommendations were suggested (a) prophylactic-intensity over intermediate-intensity anticoagulation, and (b) therapeutic-intensity over prophylactic-intensity anticoagulation. The panel issued a conditional recommendation suggesting against the use of postdischarge anticoagulant thromboprophylaxis.

conclusionsThese conditional recommendations were made based on low or very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials for patients with COVID-19.

Indexed as

AnticoagulantsCOVID-19Venous ThromboembolismHematologyHumansSARS-CoV-2Societies, MedicalUnited StatesAnticoagulants

Identifiers

PMID39437797
PMCPMC11950770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.